Literature DB >> 26045004

Development and validation of an enzyme-linked immunosorbent assay to measure adalimumab concentration.

Céline Desvignes1,2, Soujanya R Edupuganti1, François Darrouzain1,2, Anne-Claire Duveau1,2, Amy Loercher3, Gilles Paintaud1,2, Denis Mulleman1,4.   

Abstract

BACKGROUND: Adalimumab is a therapeutic antibody used for treating inflammatory diseases. To understand interindividual PK variability, there is a need to develop and validate an assay to measure serum adalimumab concentrations.
METHODS: An ELISA was developed on microtiter plates coated with TNF-α. Seven nonzero adalimumab standards ranging from 0.05 to 50 mg/l and three quality controls (0.2, 2.5 and 7 mg/l) were tested for their intra and interday precision on six occasions.
RESULTS: The LOD, LLOQ and ULOQ of the assay were 0.022, 0.073 and 9 mg/l, respectively.
CONCLUSION: This method is accurate, reproducible and may be useful for PK studies and for therapeutic drug monitoring of adalimumab.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26045004     DOI: 10.4155/bio.15.30

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  4 in total

Review 1.  Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.

Authors:  Manca Ogrič; Matic Terčelj; Sonja Praprotnik; Matija Tomšič; Borut Božič; Snezna Sodin-Semrl; Saša Čučnik
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring.

Authors:  Meenu Wadhwa; Chris Bird; Eleanor Atkinson; Isabelle Cludts; Peter Rigsby
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

3.  Relationship between clinical remission of perianal fistulas in Crohn's disease and serum adalimumab concentrations: A multi-center cross-sectional study.

Authors:  Laura Sirmai; Anne-Laure Pelletier; Nathalie Gault; Camille Zallot; Guillaume Bouguen; Dominique Bouchard; Pascale Roland Nicaise; Marine Peyneau; Sandrine Sironneau; Marcelo De Carvalho Bittencourt; Antoine Petitcollin; Pedro Fernandez; Xavier Roblin; Laurent Siproudhis; Laurent Abramowitz
Journal:  World J Gastroenterol       Date:  2022-03-07       Impact factor: 5.742

4.  Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial.

Authors:  Emilie Ducourau; Theo Rispens; Marine Samain; Emmanuelle Dernis; Fabienne Le Guilchard; Lucia Andras; Aleth Perdriger; Eric Lespessailles; Antoine Martin; Grégoire Cormier; Thomas Armingeat; Valérie Devauchelle-Pensec; Elisabeth Gervais; Benoit Le Goff; Annick de Vries; Eric Piver; Gilles Paintaud; Céline Desvignes; David Ternant; Hervé Watier; Philippe Goupille; Denis Mulleman
Journal:  RMD Open       Date:  2020-01-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.